Neoleukin Therapeutics, Inc.
Neoleukin Therapeutics, Inc. (NLTX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
nltx · stock forecast · 14 analysts (3M) · FMP · updated Apr 11, 2025
Analyst Rating & Consensus
Based on 14 Wall Street analysts in the past 3 months
Hold
14 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $3.49
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $3.47 | ↓ 0.50% |
1-day model range: $3.42–$3.53. Peak: $3.53 (-0.50%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | — | -50.0% |
| 2028 | — | -62.5% |
| 2029 | — | -67.2% |
| 2030 | — | -69.2% |
| 2031 | — | -70.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · NLTX · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-05-09 | Mizuho | Maintains | Neutral→Neutral |
| 2023-05-08 | Mizuho | Maintains | Neutral→Neutral |
| 2023-01-03 | Guggenheim | Downgrade ↓ | Buy→Neutral |
| 2023-01-02 | Guggenheim | Downgrade ↓ | Buy→Neutral |
| 2022-11-16 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2022-11-15 | Mizuho | Downgrade ↓ | Buy→Neutral |
| 2022-11-15 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2022-11-15 | Canaccord Genuity | Downgrade ↓ | Buy→Hold |
| 2022-11-15 | Guggenheim | Downgrade ↓ | Buy→Neutral |
| 2022-11-15 | Stifel | Downgrade ↓ | Buy→Hold |
Wall Street analysts have recently issued updated ratings on Neoleukin Therapeutics, Inc. (NLTX) stock. Of the recent 45 rating actions, 0 were upgrades and 19 were downgrades. 14 analysts currently cover NLTX.
Analyst Recommendation Trends
NLTX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$170M
Revenue Next Year
$0M
↓ 100.0% YoY
EPS This Year
$1.78
EPS Next Year
$-4.41
↓ 347.8% YoY
EPS ForecastReported vs Estimated
Analysts forecast NLTX EPS of $1.78 for the current fiscal year, based on estimates from 0 analysts. The NLTX revenue forecast is $170M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The NLTX stock forecast is supported by two independent data sources: analyst consensus ratings from 14 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus NLTX price target is $0.00 (+0.0% upside), with an analyst consensus of Hold.
The NLTX short-term stock prediction for tomorrow is $3.47 (-0.50%). The NLTX stock prediction for 2030 projects a range of $1–$1.
Neoleukin Therapeutics, Inc. trades on NASDAQ under the ticker NLTX. The NLTX stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 36% of covering analysts.
Frequently asked questions
NLTX forecast · 8 questionsAccording to 14 Wall Street analysts, the average 12-month NLTX price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $3.49.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.